Soft Tissue Allografts Market Share

Soft Tissue Allografts Market | Allergan completed the acquisition of Acelity L.P. Inc.’s LifeCell Corporation for US$2.9 bn in February 2017. Soft Tissue Allografts Market | Allergan completed the acquisition of Acelity L.P. Inc.’s LifeCell Corporation for US$2.9 bn in February 2017.

13.10.2017 Views

Soft Tissue Allografts Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025 A fresh study by Transparency Market Research (TMR) notifies that the global soft tissue allografts market was dominated by Allergan, plc. in 2016, and the company is poised to sustain its strong market position in the near future via its impressive product portfolio, geographical presence, and frequent strategic acquisitions. For example, Allergan completed the acquisition of Acelity L.P. Inc.’s LifeCell Corporation for US$2.9 bn in February 2017. This move will help the company to make a foray into regenerative medicine and add to its high-quality and durable portfolio. Besides the commercial products of LifeCell, Allergan will also acquire the New Jersey Company’s innovative manufacturing capabilities and its research and development operations. Browse Full Research Report: https://www.transparencymarketresearch.com/soft-tissue-allograftsmarket.html The TMR report also identifies some of the other prominent companies currently operating in the global soft tissue allografts market, namely Zimmer Biomet, Lattice Biologics Ltd., AlonSource Group, AlloSource, MiMedix Group, Inc., CONMED Corporation, Organogenesis Inc., RTI Surgical, Inc., Integra LifeSciences Corporation, Globus Medical Inc, Straumann Holding AG, Osiris Therapeutics, Inc., Arthrex, Inc., Xtant Medical, Alliqua BioMedical, Inc, C. R. Bard, Inc (Davol Inc.), B. Braun Melsungen AG, and Bone Bank Allograft. As per the projections of the TMR report, the demand in the global soft tissue allografts market will swell at a healthy CAGR of 6.3% during the forecast period of 2017 to 2025. The report estimates the market for soft tissue allografts, across the world, to be worth US$6.2 bn by the end of 2025, substantially up from its evaluated valuation of US$3.6 bn in 2016. Based on

<strong>Soft</strong> <strong>Tissue</strong> <strong>Allografts</strong> <strong>Market</strong> - Global Industry Analysis, Size,<br />

<strong>Share</strong>, Growth, Trends and Forecast 2017 - 2025<br />

A fresh study by Transparency <strong>Market</strong> Research (TMR) notifies that the<br />

global soft tissue allografts market was dominated by Allergan, plc. in 2016,<br />

and the company is poised to sustain its strong market position in the near<br />

future via its impressive product portfolio, geographical presence, and<br />

frequent strategic acquisitions. For example, Allergan completed the<br />

acquisition of Acelity L.P. Inc.’s LifeCell Corporation for US$2.9 bn in<br />

February 2017. This move will help the company to make a foray into<br />

regenerative medicine and add to its high-quality and durable portfolio.<br />

Besides the commercial products of LifeCell, Allergan will also acquire the<br />

New Jersey Company’s innovative manufacturing capabilities and its<br />

research and development operations.<br />

Browse Full Research Report:<br />

https://www.transparencymarketresearch.com/soft-tissue-allograftsmarket.html<br />

The TMR report also identifies some of the other prominent companies<br />

currently operating in the global soft tissue allografts market, namely Zimmer<br />

Biomet, Lattice Biologics Ltd., AlonSource Group, AlloSource, MiMedix<br />

Group, Inc., CONMED Corporation, Organogenesis Inc., RTI Surgical, Inc.,<br />

Integra LifeSciences Corporation, Globus Medical Inc, Straumann Holding<br />

AG, Osiris Therapeutics, Inc., Arthrex, Inc., Xtant Medical, Alliqua<br />

BioMedical, Inc, C. R. Bard, Inc (Davol Inc.), B. Braun Melsungen AG, and<br />

Bone Bank Allograft.<br />

As per the projections of the TMR report, the demand in the global soft tissue<br />

allografts market will swell at a healthy CAGR of 6.3% during the forecast<br />

period of 2017 to 2025. The report estimates the market for soft tissue<br />

allografts, across the world, to be worth US$6.2 bn by the end of 2025,<br />

substantially up from its evaluated valuation of US$3.6 bn in 2016. Based on


product type, collagen allograft was the most profitable segment, owing to its<br />

applications in aesthetics surgery, wound care, and orthopedic surgeries.<br />

Application-wise, wound care category held major market share in 2016,<br />

followed by dentistry. Geographically, North America currently serves the<br />

maximum demand in the global soft tissue allografts market.<br />

For well over a century, soft tissue allografts have been considered a<br />

successful procedure, and each year, nearly 1 million allografts are<br />

transplanted in the U.S. alone. <strong>Soft</strong> tissue allografts are substitute tissues that<br />

are used to reconstruct deficient ligaments, spinal surgery, torn menisci, and<br />

osteochondral defects during knee surgery. <strong>Soft</strong> tissue allografts undergo a<br />

three-stage safety screening process of donor screening, laboratory testing,<br />

and tissue preparation. <strong>Soft</strong> tissue allografts can be made up of bone, tendons,<br />

cartilage, skin, heart valves, and veins used for transplant in different types of<br />

surgeries.<br />

In the recent past, the usage of soft tissue allografts has grown due to increase<br />

in the number of cases in dental implants and orthopedic surgery. Escalating<br />

geriatric population, growing demand for new technological advancement for<br />

production of new tissues by tissue banks, and rise in demand of soft tissue<br />

allografts among athletes of numerous sports and other walks of life are some<br />

of the key factors driving the demand in the global soft tissue allografts<br />

market. Increase in ACL surgery, escalating incidences of diabetes foot ulcer,<br />

growing popularity of cosmetic surgery to treat facial disorders with new<br />

technologies are some of the other factors favoring the global soft tissue<br />

allografts market.<br />

While high cost of procedures continues to challenge the market for soft<br />

tissue allografts, especially in the emerging economies, the lack of defined


eimbursement policies is also obstructing the market expansion. In addition<br />

to that, complications pertaining to increased risk of infection and immune<br />

response such as disruption of infected anastomotic rigid line with a rupture,<br />

microbial infection, and bowel formation is hindering the proper prosperity of<br />

the global soft tissue allografts market.<br />

Browse Full Press Release:<br />

Press Release


About Us<br />

Transparency <strong>Market</strong> Research (TMR) is a global market intelligence<br />

company providing business information reports and services. The<br />

company’s exclusive blend of quantitative forecasting and trend analysis<br />

provides forward-looking insight for thousands of decision makers. TMR’s<br />

experienced team of analysts, researchers, and consultants use proprietary<br />

data sources and various tools and techniques to gather and analyze<br />

information.<br />

TMR’s data repository is continuously updated and revised by a team of<br />

research experts so that it always reflects the latest trends and information.<br />

With extensive research and analysis capabilities, Transparency <strong>Market</strong><br />

Research employs rigorous primary and secondary research techniques to<br />

develop distinctive data sets and research material for business reports.<br />

Contact Us<br />

Transparency <strong>Market</strong> Research<br />

State Tower,<br />

90 State Street, Suite 700,<br />

Albany NY - 12207<br />

United States<br />

USA - Canada Toll Free: 866-552-3453<br />

Email: sales@transparencymarketresearch.com<br />

Website: http://www.transparencymarketresearch.com

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!